Arca
Skip to content
Tools
Tools

Hypotension

Drug research and approvals for hypotension: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 164 studies of hypotension are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 2 approved and 2 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 164
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 2
  • EU medicines: 2

Recruiting now

Newest posted first, of 164 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 5

Phase 3 6

Phase 2 12 of 16

Phase 1 or earlier 8

How its trials ended

994 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 163 whose ending is known, 46% met their primary endpoint, 9% missed it and 45% stopped early.

  • Completed, result not reported47348%
  • Ongoing20521%
  • Status unknown15315%
  • Met its primary endpoint758%
  • Stopped: other or unclear495%
  • Stopped: enrollment or feasibility162%
  • Missed its primary endpoint152%
  • Stopped: funding4<1%
  • Stopped: sponsor or business decision3<1%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Mar 26, 2026Controlled CO2 inhalation to increase blood pressure in neurogenic orthostatic hypotension: a proof-of-concept novel therapy studyCarbon dioxideGovernors of The University of CalgaryOngoing
Jan 27, 2020A phase 3, 182-week, open-label, safety and tolerability study of TD-9855 in treating symptomatic neurogenic orthostatic hypotension (SNOH) in subjects with…Ampreloxetine (TD-9855)Theravance BiopharmaClosed
Jun 24, 2019A phase 3, 22-week, multi-center, randomized withdrawal study of td¿9855 in treating symptomatic neurogenic orthostatic hypotension in subjects with primary…Ampreloxetine (TD-9855)Theravance BiopharmaClosed
Feb 28, 2019A phase 3, 4-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of TD-9855 in treating symptomatic neurogenic orthostatic…Ampreloxetine (TD-9855)Theravance BiopharmaClosed
Jan 20, 2016Norepinephrine to prevent hypotension after spinal anesthesia for cesarean delivery: a dose finding studyNorepinephrineMount Sinai HospitalPending
Nov 10, 2015A phase 3, placebo-controlled, randomized, double-blind, multi- center study of LJPC-501 in patients with catecholamine-resistant hypotension (CRH)LJPC-501La Jolla PharmaceuticalOngoing
May 29, 2015Management of hypotension in the preterm: a multi centre, randomised, controlled trial of hypotension management in the extremely low gestational age new-bornDopamineBrepco Biopharma LimitedClosed
Dec 11, 2013Phoenix: a clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapyDroxidopaChelsea TherapeuticsOngoing
Nov 5, 2013Acarbose and older adults with postprandial hypotensionAcarboseDr Kenneth MaddenOngoing

FDA orphan designations

Approved first, then open designations, newest first
Feb 18, 2014NortheraTreatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic…Lundbeck LLCApproved
Sep 6, 1996AmatineTreatment of symptomatic orthostatic hypotension.Takeda Development Center Americas, Inc.Approved
May 9, 2023AmpreloxetineTreatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophyTheravance Biopharma Ireland LimitedDesignated
Aug 29, 2016S-ethylisothiourea diethylphosphateTreatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period.TrioxBio, Inc.Designated

Medicines authorised in the EU

Newest first
May 27, 2024NeoatriconDopamine hydrochlorideBrePco Biopharma LimitedEMA ↗
Aug 23, 2019GiaprezaAngiotensin IIPaion Pharma GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.